Organon & CO 10-K annual reports

Organon & Co. reported a 3% decrease in 2025 worldwide sales to $6.2 billion, a $301 million goodwill impairment, and identified material weaknesses in internal controls, while pursuing debt reduction and portfolio adjustments.

Organon & Co. filed an amended annual report disclosing an internal investigation into improper Nexplanon sales practices and material weaknesses in internal controls, leading to executive changes.

Organon & Co. reports a 2% increase in worldwide sales, reaching $6.4 billion in 2024, fueled by growth in women's health and biosimilars portfolios.

Organon & Co.'s 2023 10-K filing reveals a complex financial landscape, marked by modest revenue growth, strategic acquisitions, and ongoing challenges from generic competition and pricing pressures.